These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1157 related items for PubMed ID: 15378476

  • 1. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.
    Cancer; 2004 Oct 01; 101(7):1482-9. PubMed ID: 15378476
    [Abstract] [Full Text] [Related]

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 01; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
    Health Technol Assess; 2007 Jul 01; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [Abstract] [Full Text] [Related]

  • 5. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT, Robert NJ.
    MedGenMed; 2005 Aug 24; 7(3):20. PubMed ID: 16369246
    [Abstract] [Full Text] [Related]

  • 6. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE.
    Clin Cancer Res; 2001 Dec 24; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug 01; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.
    N Engl J Med; 2003 Nov 06; 349(19):1793-802. PubMed ID: 14551341
    [Abstract] [Full Text] [Related]

  • 12. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.
    Cancer Treat Rev; 2008 Apr 06; 34(2):157-74. PubMed ID: 18164821
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.
    Ned Tijdschr Geneeskd; 2006 Dec 30; 150(52):2863-9. PubMed ID: 17319217
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB.
    Am J Health Syst Pharm; 2005 Feb 01; 62(3):266-73. PubMed ID: 15719584
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Lancet Oncol; 2008 Jan 01; 9(1):23-8. PubMed ID: 18083065
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.